Allogeneic stem cell transplantation (alloSCT) is used for treating patients with T-prolymphocytic leukemia (T-PLL). However, direct evidence of GvL activity in T-PLL is lacking. We correlated minimal residual disease (MRD) kinetics with immune interventions and T-cell receptor (TCR) repertoire diversity alterations in patients after alloSCT for T-PLL. Longitudinal quantitative MRD monitoring was performed by clone-specific real-time PCR of TCR rearrangements (n=7), and TCR repertoire diversity assessment by next-generation sequencing (NGS; n=3) Although post-transplant immunomodulation (immunosuppression tapering or donor lymphocyte infusions) resulted in significant reduction (>1 log) of MRD levels in 7 of 10 occasions, durable MRD clearance was observed in only two patients. In all three patients analyzed by TCR-NGS, MRD responses were reproducibly associated with a shift from a clonal, T-PLL-driven profile to a polyclonal signature. Novel clonotypes that could explain a clonal GvL effect did not emerge. In conclusion, TCR-based MRD quantification appears to be a suitable tool for monitoring and guiding treatment interventions in T-PLL. The MRD responses to immune modulation observed here provide first molecular evidence for GvL activity in T-PLL which, however, may be often only transient and reliant on a poly-/oligoclonal rather than a monoclonal T-cell response.

Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Hematology University Hospital Schleswig Holstein Kiel Germany

Department of Medicine 5 University Hospital Heidelberg Heidelberg Germany

Genome Biology Unit European Molecular Biology Laboratory Heidelberg Germany

Oncology Practice Darmstadt Darmstadt Germany

Bone Marrow Transplant. 2017 Apr;52(4):656. doi: 10.1038/bmt.2017.12. PubMed

Zobrazit více v PubMed

Leukemia. 2007 Feb;21(2):215-21 PubMed

Blood. 2012 Jul 19;120(3):538-51 PubMed

Haematologica. 2009 May;94(5):654-62 PubMed

Genome Res. 2009 Oct;19(10):1817-24 PubMed

Nucleic Acids Res. 2015 Jan;43(Database issue):D413-22 PubMed

Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S151-60 PubMed

Bone Marrow Transplant. 2006 Apr;37(7):709-10 PubMed

Bone Marrow Transplant. 2015 Oct;50(10):1279-85 PubMed

Leukemia. 2013 Aug;27(8):1659-65 PubMed

Blood. 2012 Aug 30;120(9):1868-76 PubMed

Eur J Haematol. 2015 Mar;94(3):265-9 PubMed

Biol Blood Marrow Transplant. 2014 Sep;20(9):1307-13 PubMed

Leukemia. 2007 Apr;21(4):604-11 PubMed

Blood. 2010 Oct 7;116(14):2438-47 PubMed

Sci Transl Med. 2012 May 16;4(134):134ra63 PubMed

Br J Haematol. 2010 Jun;149(6):907-10 PubMed

Blood. 2006 Feb 1;107(3):1116-23 PubMed

Leukemia. 2003 Dec;17(12):2257-317 PubMed

Br J Haematol. 2010 Jan;148(1):80-9 PubMed

Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21194-9 PubMed

Leukemia. 2012 May;26(5):972-6 PubMed

Sci Transl Med. 2013 Dec 4;5(214):214ra171 PubMed

Bone Marrow Transplant. 2015 Sep;50(9):1227-34 PubMed

Blood. 2007 Feb 1;109(3):910-5 PubMed

Leukemia. 2008 Jul;22(7):1377-86 PubMed

Biol Blood Marrow Transplant. 2013 Mar;19(3):366-77 PubMed

Blood. 2009 Apr 30;113(18):4153-62 PubMed

Blood. 2006 Jun 1;107(11):4563-9 PubMed

Nat Med. 2013 Mar;19(3):372-7 PubMed

Biol Blood Marrow Transplant. 2010 Apr;16(4):543-7 PubMed

Leukemia. 2002 Jul;16(7):1372-80 PubMed

Leukemia. 2004 Apr;18(4):709-19 PubMed

Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?